SARS-CoV-2 Spike-Binding Polypeptides for Blocking Viral Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a critical need for specific antiviral therapeutic agents to prevent the transmission and treat COVID-19, as the virus rapidly spreads worldwide, and existing measures like quarantine and isolation are insufficient.
Innovation Solution
Development of polypeptides that specifically bind to the Spike glycoprotein of SARS-CoV-2, inhibiting viral entry into cells by mimicking the binding of antibodies, with sequences similar to those of identified antibodies, to block the interaction with host cell receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptides specifically bind to SARS-CoV-2-Spike to inhibit viral entry, then antiviral therapeutic effectiveness is improved, but the complexity of developing and producing these polypeptides increases
Solution Approach 1:
The patent creates polypeptides that replicate the antigen-binding properties of naturally occurring antibodies by copying their variable region sequences and complementarity-determining regions (CDRs). These polypeptides are designed to mimic the binding interface of known neutralizing antibodies, allowing them to specifically recognize and bind to SARS-CoV-2 Spike protein epitopes while blocking viral entry into host cells
Solution Approach 2:
The patent segments the antibody molecule into its essential functional components - specifically the variable regions (VH and VL) containing the CDRs that form the paratope. By isolating and optimizing these critical binding segments, the invention creates simplified polypeptide structures that retain antiviral activity without requiring the full antibody complexity, thereby improving producibility while maintaining therapeutic effectiveness
2Manufacturing precision
If polypeptides are designed with specific sequences to bind SARS-CoV-2-Spike, then binding specificity is improved, but the difficulty of detecting and measuring binding affinity increases
Solution Approach 1:
The patent systematically varies key parameters of the polypeptide sequences - specifically the amino acid compositions of the CDR regions and framework regions - to optimize binding specificity. By making controlled substitutions and deletions in these critical regions, the invention fine-tunes the polypeptides' ability to recognize specific Spike protein epitopes while maintaining stability and producibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively inhibit SARS-CoV-2-Spike mediated viral entry into cells, providing a potential therapeutic approach to prevent and treat COVID-19.
Implementation Method 1
polypeptides that specifically bind SARS-CoV-2-Spike... mimicking the binding of antibodies... block the interaction with host cell receptors
Data Source
AI summary
The invention provides, in various embodiments, polypeptides that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).